NovaBridge Biosciences (NBP) Net Cash Flow (2019 - 2025)

NovaBridge Biosciences (NBP) reported Net Cash Flow of $148.1 million for Q4 2025, up 1452.58% year-over-year from $9.5 million in Q4 2024, and up 7952.96% quarter-over-quarter from $1.8 million in Q3 2025.

NovaBridge Biosciences (NBP) Net Cash Flow (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has 4 years of Net Cash Flow data on file, last reported at $148.1 million in Q4 2025.

  • Net Cash Flow for Q4 2025 came in at $148.1 million, up 1452.58% year-over-year; the trailing twelve-month figure through Dec 2025 was $149.9 million (up 2456.33% YoY), and the FY2025 annual result was $142.1 million, up 279.57% from the prior year.
  • Net Cash Flow grew to $148.1 million in Q4 2025 per NBP's latest filing, from $1.8 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $148.1 million in Q4 2025 and troughed at -$10.9 million in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 2.44 Mn
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 625.70 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -2.44 Mn
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 457.40 Mn
9 Abivax 90.15 Bn 90.15 Bn - 664,983.53
10 NovaBridge Biosciences 328.19 Mn 117.34 Mn - 148.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 148.09 Mn
Dec 31, 2025 148.09 Mn
Sep 30, 2025 1.84 Mn
Sep 30, 2025 1.84 Mn
Dec 31, 2024 -10.95 Mn
Dec 31, 2024 -10.95 Mn
Sep 30, 2024 4.59 Mn
Sep 30, 2024 4.59 Mn
Dec 31, 2020 135.69 Mn
Dec 31, 2020 135.69 Mn
Sep 30, 2020 239.14 Mn
Sep 30, 2020 239.14 Mn
Dec 31, 2019 27.05 Mn
Dec 31, 2019 27.05 Mn